title: Management of patients with polycythaemia vera: results of a survey among Swedish haematologists.
abstract: The prevailing attitudes regarding diagnostic and therapeutic procedures in patients with polycythaemia vera (PV) among Swedish haematologists were surveyed by way of a mailed questionnaire in August 2002. Among diagnostic procedures frequent use is reported for arterial O(2) saturation, spleen size determination, bone marrow histology, serum erythropoietin, serum cobalamins and leukocyte alkaline phosphatase score, while direct determination of the red blood cell mass is used infrequently (seldom or never by 82%). Among therapeutic modalities hydroxyurea and phlebotomy alone were most frequently used. The (32)P therapy was used at least sometimes by 57% of the physicians, and more widely in the university clinics. Anagrelide and alfa-interferon was used in a minority of patients only. The use of prophylactic acetylsalicylic acid was very variable. The majority of the physicians had an aim for their phlebotomy treatment at a level of 0.45 or less, but 21% used a level of 0.46-0.49 and 8% a level of 0.55-0.60 (in younger patients). The platelet level, at which myelosuppressive therapy was initiated, also varied, from 400 x 10(9)/L to >1500 x 10(9)/L. It can be concluded that in practical clinical work in Sweden the diagnosis of PV is established by frequent use of serum erythropoietin, bone marrow examination and spleen size determination. The use of different therapeutic modalities is very variable. Many physicians carry out their phlebotomy treatment with less intensity compared with national and international recommendations.
authors.affiliation: Department of Haematology, Sahlgrenska University Hospital, Göteborg, Sweden.
authors.forename: Björn
authors.initials: B
authors.lastname: Andreasson
authors.forename: Eva
authors.initials: E
authors.lastname: Löfvenberg
authors.forename: Jan
authors.initials: J
authors.lastname: Westin
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001291:Attitude of Health Personnel; D004911:Erythrocyte Volume; D004921:Erythropoietin / Q000627:therapeutic use; D019538:Health Care Surveys; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D018962:Phlebotomy; D010761:Phosphorus Radioisotopes / Q000627:therapeutic use; D010820:Physicians; D011087:Polycythemia Vera / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D011795:Surveys and Questionnaires; D013548:Sweden
chemical_list: D000970:Antineoplastic Agents; D016898:Interferon-alpha; D010761:Phosphorus Radioisotopes; D004921:Erythropoietin